Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa trial (NCT06657222). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback